What this study is
To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates.
To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after initiation of the Cardiogenic Shock team on January 1, 2017.
To collect outcomes related to implementation of mechanical circulatory support versus no circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ECMO) versus intracorporeal axial-flow (Impella).
- Assess survival at three time points.
What's being tested
- Cardiogenic Shock team activation
Intervention · PROCEDURE
Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
Study details
- Official title
- Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry)
- Sponsor
- Inova Health Care Services
- Conditions
- Cardiogenic Shock
- Enrolling
- 3,000 people
- Starts
- 2018-01-01
- Est. completion
- 2099-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 85 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients at the IHVI with documented Cardiogenic Shock team intervention for acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock.
You can't join if
- Patients under the age of 18 will be excluded.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openInova Fairfax Hospital
Falls Church, Virginia, United States
- Behnam Tehrani, MD · Contact
- Alex Truesdell, MD · Principal investigator
- Benham Tehrani, MD · Sub-investigator
Recruiting
Study team
Sponsor
Inova Health Care Services
Study ID U19-02-3438
Principal investigator
Vanessa Blumer, MD
Inova Health Care Services
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.